ONCY News and Press, Oncolytics Biotech Inc. From 11/12/19

Oncolytics Biotech (NASDAQ: ONCY ): Q3 net loss of $3.5M. Shares  +4% Press Release More news on: Oncolytics Biotech Inc., Earnings news and commentary, Healthcare stocks news, ,

Highlights positive synergies in CDK 4/6 inhibitor combination, as most recent data catalyst Management hosting conference call and webcast today at 5:00 pm ET SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 12, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ON...

Oncolytics Biotech (NASDAQ: ONCY ): Q3 Non-GAAP EPS of -$0.92 misses by $0.77 ; GAAP EPS of -$0.86 misses by $0.69 . Shares +1% Press Release More news on: Oncolytics Biotech Inc., Earnings news and commentary, Healthcare stocks news, ,

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 12, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the exercise of warrants from it's August 2019 financing. The Compa...

November 11, 2019 FN Media Group Presents USA New Group Market Commentary   Los Angeles, CA – November 11, 2019 – USA News Group – As the global oncology drug market is projected to grow at a rate of 7.6% CAGR to hit $176.5 billion by 2025 , ther...

Immuno-oncolytic virus replicates exclusively in tumor tissue and induces new T cell clones Decrease in regulatory T cells leads to increased immune surveillance to fight cancer SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 8, 2019 / Oncolytics Biotech ® I...

Oncolytics Biotech Gains on Publication of Positive REO 024 Study Results Oncolytics Biotech (NASDAQ:ONCY) (TSX:ONC) shares were higher after to the company announced that positive results from its previously announced phase 1b REO 024 study of pelareorep in combination with pembrolizumab...

Partial response of 17.4 months - beating historical overall survival data T cell receptor sequencing revealed the creation of new T cell clones during treatment, which correlates with overall survival and is being confirmed as the biomarker to be used in our registrational studies ...

Gainers : Camber Energy (NYSEMKT: CEI ) +50% . Asta Funding (NASDAQ: ASFI ) +44% .  Wright Medical Group N.V. (NASDAQ: WMGI ) +32% .  Agile Therapeutics (NASDAQ: AGRX ) +31% . YRC Worldwide (NASDAQ: YRCW ) +26% . Bellicum Pharmaceuticals (NASDAQ: BLCM ) +23% . Superior...

Adlai received National Medical Products Administration approval for phase 3 clinical trials in China SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 31, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered imm...